Proactive Investors USA & Canada | Fusion IP says phase 2 trial for Diurnal's Chronocort underway Proactive Investors USA & Canada Diurnal, one of Fusion IP's (LON:FIP) portfolio of companies, has begun the phase 2 trial for its lead product Chronocort. The first patient has been enrolled into the CATCH trial, which is aimed at people suffering from reduced level s of the key ... |
Wednesday, February 6, 2013
Fusion IP says phase 2 trial for Diurnal's Chronocort underway - Proactive Investors USA & Canada
ogarawo.wordpress.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment